Andrew Hopkins, Exscientia CEO
May 19, 2021 07:18 AM EDTUpdated 09:08 AM
Deals
AI

Bris­tol My­ers ex­pands Cel­gene-era deal with Ex­sci­en­tia, tak­ing its AI R&D en­gine to the next step

Max Gelman

Senior Editor

One day af­ter tak­ing a shot on an an­ti-TIG­IT bis­pe­cif­ic from Agenus, Bris­tol My­ers Squibb is still in a deal­mak­ing mood.

For Wednes­day’s chas­er …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

Cas­sa­va shares plunge as con­tro­ver­sial Alzheimer’s drug fails Phase 3 tri­al

Trump taps Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, sur­geon gen­er­al picks

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Bris­tol My­ers re­veals more job cuts in New Jer­sey

A service from the Financial Times